A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio

British Journal of Clinical Pharmacology

Volumn 51, Issue 4, 2001, Pages 350-354

  Boulton, David W ^a,b   Arnaud, Philippe ^a,b   Lindsay Devane, C ^a,b  

^a Laboratory of Drug Disposition and Pharmacogenetics   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cortisol ratio; CYP3A; Drug interactions; Methadone

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450 3A; HYDROCORTISONE; METHADONE;

ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG EFFECT; DRUG URINE LEVEL; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROCORTISONE; METHADONE; NARCOTICS; OXIDOREDUCTASES, N-DEMETHYLATING; PYRROLIDINES;

EID: 0035037909     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.01360.x     Document Type: Article

References (38)

1. Methadone maintenance treatment in opiate dependence: A review
2. Methadone: Outpatient titration and monitoring strategies in cancer patients
3. The pharmacokinetics of methadone in healthy subjects and opiate users
4. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone
5. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes
6. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4
7. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone
8. Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4
9. The biotransformation of methadone in man: Synthesis and identification of a major metabolite
10. Disposition of methadone in methadone maintenance
11. Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment
12. Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans
13. The increase in urinary excretion of 6-β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction
14. Urinary 6-β-hydroxycortisol in humans: Analysis, biological variations and reference ranges
15. Simultaneous determination of urinary free cortisol and 6-β-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity
16. Assessing adrenocortical activity by determining levels of urinary free cortisol and urinary 6 beta-hydroxycortisol
17. Development and application of a chiral high pressure liquid chromatography assay for pharmacokinetic studies of methadone
18. Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans - A putative measure of CYP3A induction
19. Morning spot and 24-hour urinary 6β-hydroxycortisol to cortisol ratios: Intraindividual variability and correlation under basal conditions and conditions of CYP3A4 induction
20. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate
21. Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity
22. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A
23. Erythromycin breath test - Reply
24. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity
25. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men
26. Pharmacokinetics of methadone during maintenance treatment: Adaptive changes during the induction phase
27. Altered methadone pharmacokinetics in methadone-maintained pregnant women
28. Replacement of (R) -methadone by a double dose of (R,S) -methadone in addicts: Interindividual variability of the (R) / (S) ratios and evidence of adaptive changes in methadone pharmacokinetics
29. Population pharmacokinetics of methadone in opiate users: Characterization of time-dependent changes
30. Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome
31. Phenytoin and methadone tolerance
32. Rifampin-induced methadone withdrawal
33. Methadone withdrawal when starting an antiretroviral regimen including nevirapine
34. Decreased methadone effect after ritonavir initiation
35. The effect of fluconazole on the clinical pharmacokinetics of methadone
36. High interindividual variability of methadone enantiomer blood levels to dose ratios
37. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: Role of the variants of alpha1-acid glycoprotein